18:26 , Nov 7, 2018 |  BioCentury  |  Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
19:30 , Jul 27, 2018 |  BC Extra  |  Company News

I-Mab, ABL partner in antibody deals

I-Mab Biopharma (Shanghai, China) granted ABL Bio Inc. (Seongnam, South Korea) rights to bispecific antibodies against an undisclosed target for $2.5 million up front and up to $97.5 million in milestones, plus royalties. ABL will...
19:32 , Jul 13, 2018 |  BC Week In Review  |  Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
23:03 , Jul 2, 2018 |  BC Extra  |  Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
20:14 , Jun 15, 2018 |  BC Week In Review  |  Financial News

ABL snags $65M in series C

ABL Bio Inc. (Seongnam, South Korea) raised $65 million on June 8 in a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad Asset Management and Hana Financial Investment....
22:43 , Jun 8, 2018 |  BC Extra  |  Financial News

ABL snags $65M in series C

ABL Bio Inc. (Seongnam, South Korea) raised $65 million in a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad Asset Management and Hana Financial Investment. ABL has now...
23:38 , Nov 21, 2016 |  BioCentury  |  Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...